Recruitment Status

Active, not recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 1:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10531

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
Interventions: Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 4
States / cities: Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 1 more

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Buffalo, New York + 3 more

Conditions: Lymphoma
Interventions: Rituximab, Lenalidomide, Valemetostat; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 743 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2036
U.S. locations: 19
States / cities: San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more

Conditions: Crohn's Disease
Interventions: Guselkumab; Drug
Lead sponsor: Janssen-Cilag Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: San Francisco, California • Chicago, Illinois • St Louis, Missouri + 1 more

Conditions: Breast Cancer, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Prostate Cancer, Bladder Cancer
Interventions: Assessment tool IA3-CP with SDoH, Assessment tool IA3-CP without SDoH; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 65 Years to 111 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Multiple Myeloma
Interventions: Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Gilbert, Arizona • Denver, Colorado • Weston, Florida + 4 more

Conditions: Arthroplasty, Replacement, Shoulder
Interventions: Reverse Total Shoulder; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 22 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Atlantis, Florida • Waltham, Massachusetts • Grand Rapids, Michigan + 12 more

Conditions: Multiple Myeloma
Interventions: Daratumumab, Talquetamab, Teclistamab, Pomalidomide; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Duarte, California • Irvine, California • San Francisco, California + 6 more

Conditions: Crohn's Disease
Interventions: Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 109
States / cities: Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more

Conditions: Plaque Psoriasis
Interventions: JNJ-77242113, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 28
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Encinitas, California + 24 more

Conditions: Colorectal Cancer, Minimal Residual Disease
Interventions: Fludarabine Phosphate, Cyclophosphamide, Cetuximab, TROP2-CAR-NK Cells, Rimiducid (AP1903), Lymphodepleting Chemotherapy; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Active, not recruiting clinical trials

Filter and sort this status page

Live official records

A Long-term Extension Study of Ustekinumab in Pediatric Participants

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

Integrated Actionable Aging Assessment for Cancer Patients Pilot

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

INHANCE Stemless Reverse Shoulder IDE

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)